YM Biosciences Report issue

For profit Phase 2 Phase 3
Founded: Toronto Canada (1994)
Status: Acquired by Gilead Sciences (2013)

Organization Overview

First Clinical Trial
2001
NCT00708318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CIMYM BioSciences | YM BioSciences | YM Biosciences Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: YM Biosciences (1) Acquired (2)

doxorubicin (Doxil) (1 trial)

nolatrexed (1 trial)

tesmilifene (3 trials)

Drugs in Phase 2 Trials (3)

fentanyl (Innovar) (5 trials)

momelotinib (Ojjaara) (1 trial)

nimotuzumab (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioma (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Pain, Postoperative (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 6